Integra LifeSciences Holdings Corporation Q1 FY2026 earnings call

Stuart Essig stepped back into the role as president and CEO. Mike McBreen was appointed Chief Commercial Officer. First quarter delivered strong revenue and adjusted earnings per share. Segments renamed: Codman Specialty Surgical to Specialty Surgery, Tissue Technologies to Tissue Reconstruction. Tissue Reconstruction saw strong growth. Braintree facility expected to start production by end of June, Surgimend to relaunch by end of year.

First quarter total revenue was $392 million. Adjusted earnings per share was 54 cents. Specialty Surgery's revenues was $283 million, up 0.9% on a reported basis, with organic revenue down 0.6%. Tissue Reconstruction revenues were $109 million, representing 6.7% growth on a reported and 6.4% on an organic basis compared to the prior year.

Maintaining 2026 revenue guidance of $1.66 billion to $1.7 billion. Updating adjusted earnings per share guidance to $2.40 to $2.50. Second quarter revenues expected in range of $410 to $425 million. Full year gross margins and adjusted EBITDA margins expected to improve compared to 2025.

Compliance Master Plan remediation work progress, product supply recovery status, international market demand and supply affected by seasonality and macro factors.

Q: Good morning. Thank you for taking the question. Stuart, welcome back, and I'd love to hear a little bit more about why this is the right time for this transition and Any differences in your approach versus prior management in terms of how to execute on the significant priorities you have in this compliance plan and the recovery of the products that have been out of the market?

A: Matt, I am excited to be back speaking with the analysts again...

Q: Maybe just on a different topic. You provided some color on the call for Q2 and the phasing there. I just wanted to better understand key assumptions around the step-up in revenue through the year and then what's weighing on earnings in Q2 and how that evolves through the second half as well?

A: Thanks for the question, Matt... And so on through various questions and answers from different analysts